Abstract
Heptapeptide, including seven amino acids of the PKCδ V5 region, which can bind HSP27 and abrogate HSP27-mediated resistance against IR and cisplatin (Kim et al., 2007), was examined for single- and repeated-dose toxicity in mice. The single-dose experiment was performed with an intravenous and intraperitoneal injection of 100mg/kg of heptapeptide, and the repeated-dose experiment was 14 doses over 28 days at 0, 5, 25, and 100mg/kg of heptapeptide. Observations included clinical signs, mortality, body and organ weights, hematology, and serum biochemistry. No effects of heptapeptide on detected parameters were observed, and these findings indicated heptapeptide may be a possible therapeutic candidate without significant toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 284-290 |
| Number of pages | 7 |
| Journal | Drug and Chemical Toxicology |
| Volume | 33 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 2010 |
Bibliographical note
Funding Information:This study was supported by a grant from the Korea Healthcare Technology R&D Project of the Ministry for Health, Welfare, and Family Affairs (A080997) and by a grant from the Nuclear Research and Development Program of the National Research Foundation of the Ministry for Education, Science, and Technology (grant code: M2AMA006) of the Korean government. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Keywords
- Heptapeptide
- HSP27
- PCKδ
- Safety
- Toxicology
